

CURRENT PERSPECTIVES IN HAEMATOLOGICAL MALIGNANCIES

Thursday 11th October 2018

Manchester Conference Centre, Sackville Street, Manchester M1 3BB

Chairs: Dr Mike Dennis and Professor Tim Illidge (Manchester)

10.30 *Registration*

11.15 **Workshop: AML**

- The new drugs we have available
- The trials
- Patient based discussion

Dr Steve Knapper
University Hospital of Wales

Dr Mike Dennis
Christie Hospital, Manchester

12.30 *Lunch*

13.30 Continuous therapy in myeloma – the future
(5 mins Q)

Professor Graham Jackson
NCCC, Newcastle

14.05 CLL - heading for a cure?
(5 mins Q)

Dr George Follows
Addenbrooke's Hospital, Cambridge

14.40 **DEBATES:**

ECHELON 1 : Brentuximab should be used first line
in advanced Hodgkin lymphoma

Chair: Dr Andrew McMillan, Nottingham
For: Professor Tim Illidge, Manchester
Against: Dr Wendy Osborne, Newcastle

GALLIUM : Obinutuzumab, not rituximab, should
be used first line for patients with symptomatic
follicular lymphoma

Chair: Professor Tim Illidge, Manchester
For: Dr Wendy Osborne, Newcastle
Against: Dr Andrew McMillan, Nottingham

15.50 *Coffee*

16.10 High risk and resistant CML: new diagnostic tools
and treatment approaches (5 mins Q)

Dr Hugues de Lavallade
King's College Hospital, London

16.45 Myeloproliferative neoplasms - current thinking
(5 mins Q)

Professor Claire Harrison
Guy's and St Thomas' Hospital, London

17.20 *Close*

REGISTRATION:

STANDARD (until 25 th September)	LATE (from 26 th September)
Consultants: £72 Trainees/Nurses: £60 20 free places available for Trainees/Nurses	£108

Fees inclusive of VAT at 20%

Online registration now open at www.hartleytaylor.co.uk

To check availability for one of the free places or for any further information, please contact
alex@hartleytaylor.co.uk or telephone 01565 621967

This meeting is kindly sponsored by:



The sponsors have had no influence over the content of the agenda or speaker selection